Navigation Links
Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting
Date:5/5/2008

HONOLULU, HI, May 4, 2008 MedImmune today announced that researchers are currently presenting results from a MedImmune-sponsored Phase 3 study involving motavizumab, an investigational monoclonal antibody (MAb) that is being evaluated for its potential to prevent serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. Kate OBrien, M.D., M.P.H., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, is the studys principal investigator. Aruna Chandran, M.D., M.P.H., a trial co-investigator, presents the data today at the Pediatric Academic Societies (PAS) Annual Meeting in Honolulu, HI.

This randomized Phase 3 study demonstrated that motavizumab reduced hospitalizations due to RSV by 83 percent as compared to placebo (8.3 percent in placebo arm versus 1.4 percent in motavizumab; p<0.001), as the trials primary endpoint. In addition, the trial showed a 71-percent reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5 percent in placebo group and 2.8 percent in the motavizumab group; p<0.001), which was a secondary endpoint.

The randomized, double-blind Phase 3 study involving 1,410 full-term healthy infants less than six months of age in some Southwest Native American populations was designed to compare monthly intramuscular injections of motavizumab against placebo. In previous epidemiologic studies these populations were shown to have high rates of hospitalization due to RSV. This study confirmed the high rates of serious RSV disease in this population. An interim analysis, reviewed by an independent data safety monitoring committee, concluded there was statistical evidence demonstrating that motavizumab reduced RSV hospitalizations and LRIs requiring outpatient medical management within this population.

The overall incidence and severity of adverse events (AEs) were similar be
'/>"/>

Contact: Jennifer Paganelli
jennifer.paganelli@edelman.com
212-642-7774
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Wal-Mart Launches Phase Three of $4 Prescription Program
2. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
3. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
4. Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data
5. QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension
6. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
7. Many Phase 3 Cancer Drug Trials Yield Effective Medicines
8. Cancer treatments in phase 3 trials successful up to half of the time
9. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
10. MGH initiates phase I diabetes trial
11. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... NY (PRWEB) December 17, 2014 Project ... who recently brought videos of MIT economist and Obamacare ... best-selling author James O’Keefe conducted the interview, which is ... stated that there was intentional mislabeling in the Affordable ... in the bill: A two-hundred-and-fifty billion dollar per year ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Expectant parents should leave prenatal ... Administration recommends. Use of ultrasound imaging and heartbeat ... entirely risk-free, the agency warns. "Although there ... to ultrasound imaging and heartbeat monitors, prudent use of ... Shahram Vaezy, an FDA biomedical engineer, said in an ...
(Date:12/17/2014)... Alan Mozes HealthDay ... With the holiday party season fast approaching, a new study ... make DUI arrests have fewer drunk drivers on their roads. ... laws more vigilantly are better able to deter inebriated revelers ... "Hardly any new laws are being passed regarding drinking and ...
(Date:12/15/2014)... A recent survey found that the ... impacting skin health and beauty were: “Connections,” “climate,” “career” ... Water and health advocate and radio host Sharon Kleyne ... the survey and the Four C’s.* Kleyne notes, however, ... discussed would benefit from paying attention to one’s daily ...
(Date:12/15/2014)... 2014 Main Street Dental Team ( ... in on a new study providing evidence on the ... hygiene of children. , Sufficient enough evidence already exists ... pop or juice drinks, with the onset of tooth ... whether drinks listed as 100% fruit juice, meaning it ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... CHARLOTTE, N.C., Oct. 27 In conjunction with National Respiratory ... sleep support and comfort industry, is proud to promote the ... work with CPAP patients daily. One of the most ... with their CPAP mask, as a result of the mask ...
... www.polarusa.com ), the leader in heart rate ... introduced two new training computers designed to help exercisers improve their ... easy-to-use features including heart rate, which can motivate anyone to be ... heart rate monitor for the first time or looking for new ...
... Oct. 27 Life Extension® the global authority ... a provider of scientific information on anti-aging supplements ... product formulated with 50 mg of Setria® Glutathione ... C is available from Life Extension® in 100 ...
... Want Liability Reform Included in Health Care Reform Le ... overwhelmingly support meaningful medical liability reform and agree that changes ... in health care reform legislation passed by the Congress, according ... on Liability and Access. , "The HCLA poll clearly ...
... 2009) An epidemiological study on pneumonia and influenza (P&I) ... with dementia are diagnosed with flu less frequently, have ... rate of death than those without dementia. The three-pronged ... and the relationship between P&I and health care accessibility, ...
... ... of hope to refugees. , ... Kampala, Uganda (Vocus) October 27, 2009 -- From October 23-30, 2009, the United Nations ... travel to refugee camps in Uganda to help distribute anti-malaria bed nets. Nothing But ...
Cached Medicine News:Health News:Contour Products Promotes Survey for National Respiratory Care Week, Findings Prove Benefits of Contour CPAP Pillow for Sleep Apnea Patients 2Health News:Contour Products Promotes Survey for National Respiratory Care Week, Findings Prove Benefits of Contour CPAP Pillow for Sleep Apnea Patients 3Health News:Two New Easy-To-Use Training Computers from Polar Simplify the Benefits of Exercising with Heart Rate 2Health News:Two New Easy-To-Use Training Computers from Polar Simplify the Benefits of Exercising with Heart Rate 3Health News:Life Extension(R) Introduces Glutathione, Cysteine & C Formulation With Setria(R) From Kyowa Hakko USA 2Health News:New Poll Shows Americans Want Medical Liability Reform 2Health News:Older patients with dementia at increased risk for flu mortality 2Health News:Nothing But Nets Delivers Anti-Malaria Nets to Children and Families in Uganda 2Health News:Nothing But Nets Delivers Anti-Malaria Nets to Children and Families in Uganda 3
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today announced completion of enrollment in its first Phase ... 3-month observations confirmed the 1-month findings that were ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... CITY, Calif., Jan. 4, 2011 Arstasis is pleased ... to physicians, nurses, patients, and cath lab technicians across ... of physicians participating in Arstasis clinical trials and select ...  As of today, the company is making the simple-to-use, ...
... 4, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ... Recent Advances in Isis, Development PipelineWhen: , Thursday, ... 9:00 a.m. PTWhere: , www.isispharm.comHow: , Live on ... listed above. Contacts: , Kristina LemonidisDirector, Investor Relations(760) ...
Cached Medicine Technology:Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
Medicine Products: